Posterolateral lumbar spine fusion using a novel demineralized bone matrix: a controlled case pilot study

Détails

Ressource 1Télécharger: REF.pdf (238.56 [Ko])
Etat: Public
Version: Final published version
Licence: Non spécifiée
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
ID Serval
serval:BIB_F903B0E99CE4
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Posterolateral lumbar spine fusion using a novel demineralized bone matrix: a controlled case pilot study
Périodique
Archives of Orthopaedic and Trauma Surgery
Auteur⸱e⸱s
Schizas  C., Triantafyllopoulos  D., Kosmopoulos  V., Tzinieris  N., Stafylas  K.
ISSN
0936-8051
Statut éditorial
Publié
Date de publication
2008
Peer-reviewed
Oui
Volume
128
Numéro
6
Pages
621-5
Langue
anglais
Notes
DA - 20071105 LA - ENG PT - JOURNAL ARTICLE
Résumé
INTRODUCTION: Intertransverse posterolateral fusion along with instrumentation is a common technique used for spinal fusion. Iliac crest bone graft (ICBG) offers good fusion success rates with a low risk for disease transmission but is, however, linked with certain morbidity. In an effort to eliminate or reduce the amount of iliac graft needed, bone substitutes including demineralized bone matrix (DBM) have been developed. This study evaluates a novel DBM (Accell Connexus((R))) used in one or two-level instrumented posterolateral lumbar fusion. MATERIALS AND METHODS: A total of 59 consecutive patients were studied as two groups. Group 1 consisted of 33 patients having Accell Connexus((R)) used to augment either ICBG or local decompression material. Group 2 consisted of 26 consecutive patients, operated prior to the introduction of this novel DBM, having either ICBG alone or local decompression material. Fusion was assessed by two independent observers, blinded to graft material, using standardized criteria found in the literature. All adverse events were recorded prospectively. RESULTS: The results show no statistically significant differences between the two groups in fusion rates, complications, surgery duration, ODI, or pain on VAS. Logistical regression showed no relation between fusion and age, smoking status or comorbidities. Furthermore, no adverse events related to the use of the novel DBM were observed. CONCLUSION: The results from this study demonstrate that the novel DBM presented performs equally as well as that of autologous bone, be it either ICBG or a local decompression material, and can therefore be used as a graft extender.
Pubmed
Web of science
Open Access
Oui
Création de la notice
29/02/2008 13:58
Dernière modification de la notice
14/02/2022 8:57
Données d'usage